Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 198.19M | 263.60M | 311.12M | 338.57M | 236.57M |
Total Receivables | -- | -- | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 7.16M | 4.13M | 6.89M | 8.25M | 12.54M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 205.35M | 267.73M | 318.00M | 346.82M | 249.10M |
|
|||||
Total Current Assets | 205.35M | 267.73M | 318.00M | 346.82M | 249.10M |
Net Property, Plant & Equipment | 53.00K | 69.00K | 42.00K | 51.00K | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 499.00K | 452.00K | 449.00K | 379.00K | 51.00K |
Total Assets | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M |
|
|||||
Total Accounts Payable | 479.00K | 3.11M | 1.71M | 4.26M | 601.00K |
Total Accrued Expenses | 14.17M | 28.22M | 26.69M | 14.94M | 9.88M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 14.65M | 31.32M | 28.40M | 19.20M | 10.48M |
|
|||||
Total Current Liabilities | 14.65M | 31.32M | 28.40M | 19.20M | 10.48M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 14.65M | 31.32M | 28.40M | 19.20M | 10.48M |
|
|||||
Common Stock & APIC | 493.78M | 490.50M | 487.33M | 484.26M | 365.86M |
Retained Earnings | -302.52M | -253.57M | -197.23M | -156.22M | -124.71M |
Treasury Stock & Other | -- | -- | -- | -- | -- |
Total Common Equity | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M |
|